New developments and therapies in pediatric endocrinology

Evelien F Gevers^{1

2}, J Peter de Winter^{3

4

5}

Affiliations

¹ Centre for Endocrinology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom. evelien.gevers@nhs.net.
² Department of Paediatric Endocrinology and Diabetes, Barts Health NHS Trust - The Royal London Children's Hospital, London, United Kingdom. evelien.gevers@nhs.net.
³ Department of Pediatrics, Spaarne Gasthuis, Haarlem/Hoofddorp, The Netherlands.
⁴ Leuven Child and Health Institute, KU Leuven, Leuven, Belgium.
⁵ Department of Development and Regeneration, KU Leuven, Leuven, Belgium.

Editorial

Evelien F Gevers et al. Eur J Pediatr. 2023 Apr.

. 2023 Apr;182(4):1439-1443.

doi: 10.1007/s00431-022-04772-6.

Evelien F Gevers^{1

2}, J Peter de Winter^{3

4

5}

¹ Centre for Endocrinology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom. evelien.gevers@nhs.net.
² Department of Paediatric Endocrinology and Diabetes, Barts Health NHS Trust - The Royal London Children's Hospital, London, United Kingdom. evelien.gevers@nhs.net.
³ Department of Pediatrics, Spaarne Gasthuis, Haarlem/Hoofddorp, The Netherlands.
⁴ Leuven Child and Health Institute, KU Leuven, Leuven, Belgium.
⁵ Department of Development and Regeneration, KU Leuven, Leuven, Belgium.

Erratum in

Correction to: Editorial pediatric endocrinology series european journal of pediatrics "New developments and therapies in pediatric endocrinology".
Gevers EF, de Winter JP. Gevers EF, et al. Eur J Pediatr. 2023 Apr;182(4):1445. doi: 10.1007/s00431-023-04815-6. Eur J Pediatr. 2023. PMID: 36656374 No abstract available.

No abstract available

1. Ciancia S, Högler W, Sakkers RJB, Appelman-Dijkstra NM, Boot AM, Sas TCJ, Renes JS (2022) Osteoporosis in children and adolescents: how to treat and monitor? Eur J Pediatr
1. Ciancia S, van Rijn RR, Högler W, Appelman-Dijkstra NM, Boot AM, Sas TCJ, Renes JS (2022) Osteoporosis in children and adolescents: when to suspect and how to diagnose it. Eur J Pediatr 181:2549–2561 - PubMed - PMC - DOI
1. Maeda K, Kobayashi Y, Koide M, Uehara S, Okamoto M, Ishihara A, Kayama T, Saito M, Marumo K (2019) The regulation of bone metabolism and disorders by wnt signaling. Int J Mol Sci 20
1. Nealy KL, Harris KB (2021) Romosozumab: A novel injectable sclerostin inhibitor with anabolic and antiresorptive effects for osteoporosis. Ann Pharmacother 55:677–686 - PubMed - DOI
1. Dempster DW, Lambing CL, Kostenuik PJ, Grauer A (2012) Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data. Clin Ther 34:521–536 - PubMed - DOI